Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Multiple myeloma is most common in people age 65 and older. The average age of diagnosis is 70, with fewer than 1% of cases diagnosed in people younger than 35.

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

"Back in the 1990s, multiple myeloma was a dreaded disease and patients had dismal outcomes," Vishwanath Sathyanarayanan, MD, DM, of Apollo Cancer Centers in Bangalore, India, said in an interview.

"Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma" was originally created and published by ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Multiple myeloma (MM) is a form of blood cancer that originates from plasma cells – part of the white blood cell produced by ...

Single-dose CAR-T therapy potentially curative in multiple myeloma by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

Multiple myeloma is a type of blood cancer that starts in the bone marrow. It occurs when plasma cells, a type of white blood cell, grow uncontrollably.

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...